Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2023 Results Conference Call February 27, 2024 4:30 PM ET

Company Participants

Diane Weiser - SVP of Corporate Communication and IR

Robert Blum - President and CEO

Fady Malik - EVP of R&D

Stuart Kupfer - SVP and Chief Medical Officer

Andrew Callos - EVP and Chief Commercial Officer

Robert Wong - VP and Chief Accounting Officer

Conference Call Participants

Mayank Mamtani - B. Riley Securities

Carter Gould - Barclays

Paul Choi - Goldman Sachs

Adi Jayanthi - JP Morgan

Yasmeen Rahimi - Piper Sandler

Joe Pantginis - H.C. Wainwright

Roanna Ruiz - Leerink Partners

Billal Jahangiri - Truist Securities

Serge Belanger - Needham

Charles Duncan - Cantor Fitzgerald

Operator

Good afternoon. And welcome ladies and gentlemen to Cytokinetics Fourth Quarter 2023 Conference Call [Operator Instructions]. I will now turn the call over to Diane Weiser, Cytokinetics, Senior Vice President of Corporate Communication and Investor Relations. Please go ahead.

Diane Weiser

Good afternoon. And thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments; Fady Malik, EVP of R&D, will provide updates related to aficamten focused to SEQUOIA-HCM and FOREST-HCM; Stuart Kupfer, SVP and Chief Medical Officer, will provide additional updates for aficamten relating to SEQUOIA-HCM and MAPLE-HCM, and will also discuss CK-586 and CK-136; Andrew Callos, EVP and Chief Commercial Officer, will discuss commercial readiness activities for aficamten; Robert Wong, VP and Chief Accounting Officer, will provide a financial overview of the past quarter; and finally, Robert Blum, will provide discuss our 2024 financial guidance and corporate development strategies before closing the call by reviewing expected key milestones for the year. Please note that portions of the following discussion, including our responses to questions, contain statements that relate to future events and performance rather than historical facts and constitute forward-looking statements. Our actual results might differ materially from those projected in these forward-looking statements. Additional information concerning factors that could cause our actual results to differ materially from those in these forward-looking statements is contained in our SEC filings, including our current report regarding our fourth quarter 2023 financial results filed on Form 8-K that was furnished to the SEC today. We undertake no obligation to update any forward-looking statements after this call.

And now, I will turn the call over to Robert.

Robert Blum

Thank you, Diane. And thanks for joining us on the call today. The fourth quarter of 2023 represented a transformational inflection point for our company. As we turned the card on SEQUOIA-HCM, our Phase 3 clinical trial of aficamten for the potential treatment of patients with hypertrophic cardiomyopathy or HCM. The results exceeded our already high expectations and we began 2024 firing on all cylinders with renewed commitments to preparing for regulatory interactions and submissions with urgency, executing on the broad clinical development program following behind SEQUOIA-HCM, as well as activating the next phase of commercial readiness activities. On today's call, Fady will discuss our plans for presentation and publication of primary and other results of SEQUOIA-HCM, which will further elaborate on the efficacy and safety of our next in class cardiac myosin inhibitor. And as well, we're how we're moving swiftly to regulatory submissions across the globe. And then Andrew will comment on how we're prudently planning for differentiated commercial positioning for our next in class opportunity. As important as SEQUOIA-HCM is to our path to commercialization, there's much more in our pipeline that we believe will meaningfully unlock shareholder value as the company continues to mature. Stuart will provide an update on the progress of MAPLE-HCM and the ACACIA-HCM, the additional Phase 3 clinical trials of aficamten, which will provide an on-ramp to potentially expanding the utility of cardiac myosin inhibitors as a first line treatment for obstructive HCM, as well as potentially provide a new treatment option for the growing number of patients with non-obstructive HCM. As you will hear, there's been an increased enthusiasm and activity surrounding these trials on the heels of the positive results from SEQUOIA-HCM. However, much still remains ahead of us to bring aficamten to patients, but I'm confident in our ability to execute on our ambitious strategies.